159 related articles for article (PubMed ID: 29914268)
1. Levodopa Reduces the Phase lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study.
Cao C; Li D; Zeng K; Zhan S; Huang P; Li X; Sun B
Clin EEG Neurosci; 2019 Mar; 50(2):134-140. PubMed ID: 29914268
[No Abstract] [Full Text] [Related]
2. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
3. Functional and effective connectivity in subthalamic local field potential recordings of patients with Parkinson's disease.
Hohlefeld FU; Huchzermeyer C; Huebl J; Schneider GH; Nolte G; Brücke C; Schönecker T; Kühn AA; Curio G; Nikulin VV
Neuroscience; 2013 Oct; 250():320-32. PubMed ID: 23876322
[TBL] [Abstract][Full Text] [Related]
4. Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease.
Mueller K; Jech R; Ballarini T; Holiga Š; Růžička F; Piecha FA; Möller HE; Vymazal J; Růžička E; Schroeter ML
Cerebellum; 2019 Apr; 18(2):212-224. PubMed ID: 30298443
[TBL] [Abstract][Full Text] [Related]
5. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
[TBL] [Abstract][Full Text] [Related]
6. Increased SMA-M1 coherence in Parkinson's disease - Pathophysiology or compensation?
Pollok B; Kamp D; Butz M; Wojtecki L; Timmermann L; Südmeyer M; Krause V; Schnitzler A
Exp Neurol; 2013 Sep; 247():178-81. PubMed ID: 23664959
[TBL] [Abstract][Full Text] [Related]
7. L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients.
Cao C; Li D; Zhan S; Zhang C; Sun B; Litvak V
Neuroimage Clin; 2020; 26():102255. PubMed ID: 32361482
[TBL] [Abstract][Full Text] [Related]
8. Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease.
Vinding MC; Tsitsi P; Piitulainen H; Waldthaler J; Jousmäki V; Ingvar M; Svenningsson P; Lundqvist D
Sci Rep; 2019 Feb; 9(1):2604. PubMed ID: 30796340
[TBL] [Abstract][Full Text] [Related]
9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
10. Defective cortical drive to muscle in Parkinson's disease and its improvement with levodopa.
Salenius S; Avikainen S; Kaakkola S; Hari R; Brown P
Brain; 2002 Mar; 125(Pt 3):491-500. PubMed ID: 11872607
[TBL] [Abstract][Full Text] [Related]
11. Deficient "sensory" beta synchronization in Parkinson's disease.
Degardin A; Houdayer E; Bourriez JL; Destée A; Defebvre L; Derambure P; Devos D
Clin Neurophysiol; 2009 Mar; 120(3):636-42. PubMed ID: 19208497
[TBL] [Abstract][Full Text] [Related]
12. Differential dopaminergic modulation of spontaneous cortico-subthalamic activity in Parkinson's disease.
Sharma A; Vidaurre D; Vesper J; Schnitzler A; Florin E
Elife; 2021 Jun; 10():. PubMed ID: 34085932
[TBL] [Abstract][Full Text] [Related]
13. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.
Esposito F; Tessitore A; Giordano A; De Micco R; Paccone A; Conforti R; Pignataro G; Annunziato L; Tedeschi G
Brain; 2013 Mar; 136(Pt 3):710-25. PubMed ID: 23423673
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of STN-cortical and cortico-muscular coherence by movement and levodopa in Parkinson's disease.
Hirschmann J; Özkurt TE; Butz M; Homburger M; Elben S; Hartmann CJ; Vesper J; Wojtecki L; Schnitzler A
Neuroimage; 2013 Mar; 68():203-13. PubMed ID: 23247184
[TBL] [Abstract][Full Text] [Related]
15. Levodopa responsiveness in Parkinson's disease patients and white matter alterations in diffusion tensor imaging: a cross-sectional tract-based spatial statistics study.
Zhou W; Jiang J; Peng W; Zhou X; Du J; Mo L; Tan C; Liu X; Chen L
Neuroreport; 2021 May; 32(7):636-642. PubMed ID: 33850092
[TBL] [Abstract][Full Text] [Related]
16. Effect of L-Dopa on the pattern of movement-related (de)synchronisation in advanced Parkinson's disease.
Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Guieu JD; Destée A; Defebvre L
Neurophysiol Clin; 2003 Nov; 33(5):203-12. PubMed ID: 14672820
[TBL] [Abstract][Full Text] [Related]
17. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
18. The amplitude of low-frequency fluctuation predicts levodopa treatment response in patients with Parkinson's disease.
Yang B; Wang X; Mo J; Li Z; Gao D; Bai Y; Zou L; Zhang X; Zhao X; Wang Y; Liu C; Zhao B; Guo Z; Zhang C; Hu W; Zhang J; Zhang K
Parkinsonism Relat Disord; 2021 Nov; 92():26-32. PubMed ID: 34666272
[TBL] [Abstract][Full Text] [Related]
19. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
[TBL] [Abstract][Full Text] [Related]
20. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
